ArticleCureus2026
Single-Fraction Stereotactic Body Radiotherapy for Early-Stage Lung Adenocarcinoma Within Atelectasis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic body radiotherapy (SBRT) is an established non-invasive treatment for early-stage non-small cell lung cancer (NSCLC) in patients who are medically inoperable or who decline surgery. However, delivering SBRT to tumors within atelectasis presents unique challenges due to anatomical distortion, impaired tumor visualization, and uncertainties in target motion and localization. A 61-year-old woman with severe chronic obstructive pulmonary disease on long-term home oxygen therapy was diagnosed with biopsy-confirmed right upper lobe lung adenocarcinoma located within an area of atelectasis. She was medically inoperable due to critically reduced pulmonary reserve. Staging positron emission tomography-computed tomography (PET-CT) revealed a focal hypermetabolic right upper lobe lesion with no evidence of nodal or distant metastases. The patient received single-fraction SBRT (SF-SBRT) to 34 Gy using a 1 cm isotropic planning target volume margin to account for increased planning and treatment-related uncertainties. Target delineation was guided by PET-CT to distinguish metabolically active tumor from surrounding atelectasis, and image guidance was performed using cone-beam CT matching to surrogate anatomic landmarks due to limited direct tumor visualization. At 6.1 months after SBRT, the patient demonstrated significant metabolic response on PET-CT but developed rapidly progressive brain metastases and died 6.6 months after SBRT. This case demonstrates the feasibility of SF-SBRT for early-stage NSCLC within atelectasis. While short-term metabolic response was achieved, long-term local control remains unclear and further research into the management of lung tumors within atelectasis is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.